IFNA2 and COVID-19: Importantly, anti-IFN-β neutralizing antibodies are infrequent (≤1% of critical COVID-19), in contrast to anti-IFN-α or anti-IFN-ω antibodies, which occur in up to 20% of older patients and fatal COVID-19 (ref. 49).